NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 19.22 against a street estimate of 18.03 — a beat of 6.6%.
with an average price target of ₹2,856.07.
CONFIDENT Gland Pharma delivered strong Q1 FY'27 with 20% revenue growth and 47% PAT growth. CDMO business now 50% of revenue. Major new strategic manufacturing contract worth $90–100M potential from 2029, plus liposome and API partnerships announced. Q1 FY'27 U.S. remains largest market. ROW impacted by supply disruptions in Saudi Arabia and delayed Nucor tender results. Cenexi flat YoY but benefited from new ampoule line production ramp-up; European heat wave disrupted Q1, expected recovery in Q2. Analysts pressed on deal structure and sustainability of turnaround at ROW business (Saudi disruption, flat growth). Management clarified specialty pharma nature of contract, reiterated 20% CAGR outlook, and emphasized end-to-end solution positioning vs. fragmented competitor base. GLP-1 revenue upside flagged but immaterial near-term. 2026-08-10…
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call GLAND PHARMA LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Total Revenues: INR 18,003 million, up 20% year-on-year • Adjusted EBITDA: INR 5,102 milli | 2026-08-17 |
| Investor presentation · Q1 FY27 GLAND PHARMA Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹18,003 million in Q1 FY27, up 20% YoY from ₹15,056 million in Q1 | 2026-08-10 |
| Quarterly results · Q1 FY27 GLAND PHARMA LIMITED – Q1 FY27 RESULTS SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹18,003 million (Q1 FY27) vs ₹15,056 million (Q1 FY26) – | 2026-08-10 |
| Annual report FY2026 GLAND PHARMA LIMITED – DOCUMENT SUMMARY COMPANY INFORMATION • Company: Gland Pharma Limited (BSE Code: 543245 | NSE Symbol: GLAND | ISIN: INE068V010 | 2026-07-31 |
| Q4 FY26 earnings call GLAND PHARMA LIMITED – Q4 FY26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q4 FY26 Revenue: INR17,428 million, +22% year-on-year • Q4 FY26 Adjus | 2026-05-20 |
| Investor presentation · Q4 FY26 GLAND PHARMA LIMITED – Q4 FY26 INVESTOR SUMMARY --- HEADLINE NUMBERS • FY26 Consolidated Revenue: ₹64,307 million, up 14% YoY (Q4: ₹17,428 million, | 2026-05-15 |
| Quarterly results · Q4 FY26 GLAND PHARMA LIMITED – Q4 FY26 RESULTS SUMMARY HEADLINE NUMBERS • Full Year FY26 Revenue: ₹64,307 million, up 14.5% YoY (from ₹56,165 million in FY2 | 2026-05-15 |
| Q3 FY26 earnings call GLAND PHARMA LIMITED – Q3 FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 consolidated revenue: INR 16,954 million (up 22% year-on-year) • Q3 FY26 adjusted | 2026-02-03 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹20 / share ex-date Aug 11, 2026 | 2026-08-11 |
| Dividend | ₹18 / share ex-date Aug 14, 2025 | 2025-08-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gland Pharma Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.